Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The combination of ethambutol, isoniazid, and rifampicin is a fixed-dose medication primarily used for treating tuberculosis (TB). This combination is part of the standard treatment regimen for TB, often used in the continuation phase of treatment after the initial intensive phase.
This medication works through multiple mechanisms to combat Mycobacterium tuberculosis. Rifampicin inhibits bacterial RNA polymerase, isoniazid interferes with mycolic acid synthesis in the bacterial cell wall, and ethambutol disrupts arabinogalactan synthesis in the cell wall.
The combination is typically administered orally, with dosing based on patient weight and treatment phase. It's usually taken on an empty stomach, one hour before or two hours after meals for optimal absorption.
Several brand names exist for this combination, including:
Common side effects include:
This combination has numerous significant drug interactions:
Due to rifampicin's strong enzyme-inducing properties, alternative birth control methods are recommended for women taking hormonal contraceptives.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ethambutol + isoniazid + rifampicin.